Earnings summaries and quarterly performance for Inogen.
Executive leadership at Inogen.
Kevin R.M. Smith
Detailed
Chief Executive Officer and President
CEO
GR
Gregoire Ramade
Detailed
Executive Vice President, Chief Commercial Officer
JY
Jennifer Yi Boyer
Detailed
Executive Vice President, Enterprise Enablement and Chief Human Resources Officer
KP
Kevin P. Smith
Detailed
Executive Vice President, General Counsel, Secretary & Business Development
MW
Mary Wright
Detailed
Chief Accounting Officer
MB
Michael Bourque
Detailed
Executive Vice President, Chief Financial Officer, and Corporate Treasurer
Board of directors at Inogen.
EM
Elizabeth Mora
Detailed
Chairperson of the Board
GB
Glenn Boehnlein
Detailed
Director, Chairperson of the Audit Committee
HR
Heather Rider
Detailed
Director, Chairperson of the Nominating and Governance Committee
KK
Kevin King
Detailed
Director, Chairperson of the Compliance Committee
MK
Mary Kay Ladone
Detailed
Director, Chairperson of the Compensation Committee
MS
Mira Sahney
Detailed
Director
Research analysts who have asked questions during Inogen earnings calls.
RP
Rohin Patel
JPMorgan Chase & Co.
3 questions for INGN
Also covers: CVRX, HAE, NPCE
CC
Colin Clark
Stifel Financial Corp.
2 questions for INGN
Also covers: DXCM
Michael Matson
Needham & Company
2 questions for INGN
Also covers: AORT, ATRC, CNMD +22 more
AG
Allen Gong
JPMorgan Chase & Co.
1 question for INGN
Also covers: ESTA, GEHC, GKOS +3 more
AS
Anderson Schock
B. Riley Securities
1 question for INGN
Also covers: ANIK, CLPT, ELMD +8 more
Joseph Conway
Needham & Company, LLC
1 question for INGN
Also covers: AORT, ATRC, ENOV +6 more
MS
Max Smock
William Blair & Company
1 question for INGN
Also covers: CDMO, CERT, CRL +7 more
Mike Matson
Needham & Company, LLC
1 question for INGN
Also covers: CNMD, ENOV, ESTA +16 more
Recent press releases and 8-K filings for INGN.
Inogen Announces Preliminary Q4 and Full-Year 2025 Revenue Results
INGN
Earnings
Guidance Update
- Inogen announced preliminary, unaudited total revenue of approximately $82 million for the fourth quarter of 2025, representing year-over-year growth of approximately 2%.
- For the full year 2025, preliminary, unaudited total revenue is expected to be approximately $349 million, reflecting year-over-year growth of approximately 4%.
- The company anticipates achieving positive Adjusted EBITDA for the full year 2025.
- Management noted that Q4 results were impacted by a shift in the timing of some large customer orders into the first half of 2026.
- Inogen plans to announce full financial results and 2026 financial guidance on February 24, 2026.
Jan 12, 2026, 1:41 PM
Inogen Announces Preliminary Q4 and Full-Year 2025 Revenue Results
INGN
Earnings
Guidance Update
- Inogen announced preliminary, unaudited total revenue for Q4 2025 is estimated at approximately $82 million, reflecting 2% year-over-year growth.
- For the full year 2025, preliminary, unaudited total revenue is expected to be approximately $349 million, representing 4% year-over-year growth.
- The company anticipates achieving positive Adjusted EBITDA for the full year 2025.
- While business-to-business channels showed strong performance, Q4 results were impacted by a shift in the timing of a few large customer orders into the first half of 2026.
- Inogen plans to announce its full financial results and 2026 financial guidance on February 24, 2026.
Jan 12, 2026, 1:30 PM
Inogen Launches Aurora CPAP Masks for Obstructive Sleep Apnea
INGN
Product Launch
New Projects/Investments
- Inogen, Inc. (Nasdaq: INGN) has launched Aurora CPAP masks in the United States, marking its entry into the obstructive sleep apnea (OSA) market.
- This launch represents a pivotal step in Inogen's strategy to expand its respiratory care portfolio and addressable market opportunity within the growing sleep-therapy market.
- The Aurora Mask portfolio, which includes F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows, is designed for comfort, reliability, and usability, and is FDA 510(k) Cleared.
Jan 7, 2026, 1:30 PM
Inogen Announces Q3 2025 Financial Results
INGN
Earnings
Demand Weakening
- In Q3 2025, Inogen reported total revenue of $92.4 million, representing a 4.0% year-over-year increase.
- Business-to-business international sales were a significant contributor, growing 18.8% to $38.4 million, while direct-to-consumer domestic sales declined by 17.9% to $15.8 million.
- The company posted a GAAP net loss of $(5,294) thousand and a GAAP diluted EPS of $(0.20) for the third quarter of 2025.
- On a non-GAAP basis, Inogen's Adjusted EBITDA was $2,256 thousand and Adjusted Net Loss was $(462) thousand, leading to an Adjusted Diluted EPS of $(0.02) for Q3 2025.
Nov 5, 2025, 1:30 PM
Inogen Reports Strong Q3 2025 Results and Raises Full-Year Adjusted EBITDA Guidance
INGN
Earnings
Guidance Update
Product Launch
- Inogen (INGN) reported $92.4 million in total revenue for Q3 2025, a 4% increase year-over-year, marking its seventh consecutive quarter of mid-single-digit growth. The company achieved $2.3 million in adjusted EBITDA, its third consecutive quarter of profitability in this metric.
- The company raised its full-year 2025 adjusted EBITDA guidance to approximately $2 million from a prior break-even expectation. Full-year revenue guidance was reiterated at $354 million-$357 million.
- Growth was primarily driven by international B2B revenue, which increased 18.8% to $38.4 million, and domestic B2B revenue, which increased 6.6% to $24.9 million.
- Inogen expanded its product portfolio with the launch of the Voxy 5 stationary oxygen concentrator and the limited market release of Symbiox in the U.S..
Nov 5, 2025, 1:30 PM
Inogen Announces Third Quarter 2025 Financial Results
INGN
Earnings
Guidance Update
Product Launch
- Inogen reported total revenue of $92.4 million for the third quarter of 2025, marking a 4.0% year-over-year increase and its seventh consecutive quarter of mid-single-digit percentage growth.
- For Q3 2025, the company achieved $2.3 million in adjusted EBITDA, representing its third consecutive quarter of positive adjusted EBITDA, alongside a GAAP net loss of $5.3 million.
- Inogen generated $2.2 million in positive operating cash flow during the quarter, increasing its cash, cash equivalents, marketable securities, and restricted cash to $124.5 million as of September 30, 2025, with no outstanding debt.
- The company reiterated its full-year 2025 revenue outlook in the range of $354 million to $357 million and raised its Adjusted EBITDA guidance to approximately $2 million.
Nov 5, 2025, 12:36 PM
Inogen Announces Q2 2025 Financial Results
INGN
Earnings
Demand Weakening
- Inogen reported total revenue of $92.3 million for Q2 2025, marking a 4.0% increase year-over-year.
- The company's GAAP net loss for Q2 2025 was $(4.152) million, or $(0.15) per diluted share.
- On a non-GAAP basis, Adjusted EBITDA for Q2 2025 was $2.081 million, with an Adjusted Net Loss of $(0.650) million and Adjusted Diluted EPS of $(0.02).
- Revenue growth was primarily driven by business-to-business sales, with domestic sales increasing 19.3% to $25.4 million and international sales increasing 17.7% to $35.9 million, while direct-to-consumer domestic sales decreased 21.1% to $17.8 million.
Aug 7, 2025, 9:00 PM
Inogen Inc Adopts Amended Equity Incentive Plan
INGN
Executive Compensation
Proxy Vote Outcomes
- Equity Incentive Plan Adoption: Inogen Inc announced the adoption and amendment of its 2023 Equity Incentive Plan, which sets forth standard terms for stock options and restricted stock units, including vesting schedules and exercise provisions.
- Share Increase Approved: At the Annual Meeting on May 14, 2025, stockholders approved the amended plan, increasing the available shares by 750,000 for future awards.
- Governance and Corporate Action Provisions: The documents detail provisions for vesting acceleration, adjustments for mergers or change in control, and additional terms for participants outside the United States.
May 19, 2025, 12:00 AM
Inogen Inc Q1 2025 Financial Results & Strategic Updates
INGN
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Revenue increased to $82.3 million in Q1 2025, up 5.5% YoY and driven by stronger business-to-business sales
- GAAP net loss narrowed to $6.2 million (down from $14.6 million) with adjusted net loss improving to $2.9 million and adjusted EBITDA turning positive
- Operating expense decreased by 13.1% to $44.0 million, aiding improved operational performance
- Strategic initiatives: A $27 million investment from Yuwell supports an expanding innovation pipeline
- Guidance & liquidity: Full-year revenue projected at $352–355 million, Q2 revenue expected between $89–91 million, and a robust cash position of $122.5 million with no debt
May 7, 2025, 9:01 PM
Inogen Announces Q4 2024 Financial Results, Earnings & Strategic Initiatives
INGN
Earnings
Revenue Acceleration/Inflection
Guidance Update
Product Launch
- Q4 Financial Highlights: Revenue grew by 5.5% to $80.1 million, driven by strong domestic (up 24.1%) and international (up 31.5%) B2B performance, with improved gross margin (45.3% vs. 37.1%) and a reduction in operating loss from $29.0M to $11.4M
- Full-Year & Guidance Update: Full-year revenue increased by 6.4% to $335.7 million, with 2025 guidance expecting revenue of $352–$355 million
- Strategic Collaboration: Finalized a partnership with Yuwell Medical, involving a $27.2 million investment for a 9.9% stake, aimed at expanding market reach—particularly for stationary products in China and the U.S.
- Profitability & Financial Position: Reported a GAAP net loss of $9.8 million alongside improved adjusted measures, a robust cash position of $117.4 million, and no outstanding debt
- Product Innovation: Launched the latest portable oxygen concentrator, Rove 4, and secured FDA clearance for the Simeox airway clearance device, bolstering its innovation pipeline
Feb 25, 2025, 12:00 AM
Quarterly earnings call transcripts for Inogen.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more